Yatai pharm(SZ:002370) Tai Mei Ti A P P·2025-10-14 12:50Core Viewpoint - The control change of Asia-Pacific Pharmaceutical (002370.SZ) has been revealed, with the controlling shareholder planning to transfer 1.09 billion shares at a price of 8.26 CNY per share, totaling 900 million CNY, marking a significant shift in ownership to Xinghao Holdings and its actual controller, Qiu Zhongxun [2][3]. Group 1: Share Transfer Details - The share transfer price of 8.26 CNY per share represents a premium of 45.68% over the closing price of 5.67 CNY per share on September 26, prior to the agreement signing [3]. - The original shareholders, including Fubon Group and Han Gui Investment, will exit with nearly double their investment, achieving an approximate 80% return on their investment [6][7]. - Fubon Group and its associates acquired shares through various methods, including judicial auctions and market purchases, with an average acquisition cost estimated at 4.6 CNY per share [6][4]. Group 2: Financial Position and Future Plans - As of mid-2025, Asia-Pacific Pharmaceutical has 625 million CNY in cash and a low debt ratio of 9.14%, indicating a strong financial position [8]. - The share transfer agreement includes performance and asset quality commitments, with a target revenue of at least 360 million CNY for 2025 and a net profit loss not exceeding 70 million CNY [10]. - The company plans to transition from traditional chemical generics to innovative drug development, with a focus on potential new drug projects that have already shown preliminary research results [18][19].